Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228467 | 0.89 | CCR1 (0.40) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL1229148 | 0.88 | GAA (0.48) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL1227053 | 0.88 | GAA (0.44) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL1227005 | 0.87 | GAA (0.43) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL14880101 | 0.85 | GAA (0.38) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL14880139 | 0.85 | CCR1 (0.39) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL1228580 | 0.84 | GAA (0.44) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL1226982 | 0.84 | KDM4E (0.45) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL1227001 | 0.84 | GAA (0.42) | GAAPOLBTSHRCCR1KDM4E | |
| SCHEMBL9105865 | 0.82 | POLB (0.45) | GAAPOLBTSHRCCR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557821-B2 | Microbiocidal heterocycles | SYNGENTA CROP PROTECTION, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2464643-A1 | MICROBIOCIDAL HETEROCYCLES | Syngenta Participations AG (CH) | 2012-06-20 | — | — | EP | disclosed |
| US-20120142700-A1 | MICROBIOCIDAL HETEROCYCLES | SYNGENTA CROP PROTECTION, LLC (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011018401-A1 | MICROBIOCIDAL HETEROCYCLES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142700-A1 | MICROBIOCIDAL HETEROCYCLES | MPO, CYP51A1, CYP1A1 | GAA 560/4885POLB 1948/4885TSHR 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.